Organization Profile

You just read:

Teva Canada Announces the Approval of TRUXIMA™, the first biosimilar to RITUXAN® in Canada for the Treatment of Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Rheumatoid Arthritis

News provided by

Teva Canada

Apr 10, 2019, 08:00 ET